0001601485 false 06/24/2026 Nasdaq☒0001601485 2026-06-24 2026-06-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 24, 2026
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware | 001-39990 | 11-3430072
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.)
| 451 D Street, 5th Floor |
| Boston, Massachusetts 02210 |
| (Address of principal executive offices, including zip code) |

(857) 209-0050
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

(Title of each class) | (Trading Symbol) | (Name of exchange on which registered)
Common Stock, $0.01 par value per share | ELTX | The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.
On June 24, 2026, Elicio Therapeutics, Inc. (the “Company”) hosted a virtual key opinion leader event highlighting the path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma featuring key opinion leaders, Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program, and Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami. The presentation is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.
The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

Exhibit Number |  | Exhibit Description
99.1 |  | Company Presentation dated June 24, 2026.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | Elicio Therapeutics, Inc.
|  |  | By: |  | /s/ ROBERT CONNELLY
Date: June 24, 2026 |  |  |  |  | Robert Connelly President and Chief Executive Officer (Principal Executive Officer)